Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects-Reference-Cited by-同舟云学术

Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects

Published:2015-11-05 Issue:1 Volume:5 Page:13-26
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:

Author:

Xuan Dawei¹,McBride Scott²,Wastall Philip³,Porcari Anthony¹,DiCarlo Lorenzo⁴,Boyd Rebecca A.¹

Affiliation:

1. Pfizer Inc.; New York NY USA

2. United BioSource Corporation; Ann Arbor MI USA

3. Bristol-Myers Squibb Company; Princeton NJ USA

4. Proteus Digital Health, Inc.; Redwood City CA USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Reference23 articles.

1. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US;Heit;Blood,2005

2. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy;Hirsh;Circulation,2003

3. Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis;Leko;J Thromb Haemost,2004

4. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty;Eriksson;N Engl J Med,2008

5. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial;Kakkar;Lancet,2008

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic-Pharmacodynamic Analysis’ Role in Design of Phase ⅠClinical Trials of Anticoagulant Agents: A Systematic Review;Expert Review of Clinical Pharmacology;2020-10-27

2. Current and Emerging Direct Oral Anticoagulants: State-of-the-Art;Seminars in Thrombosis and Hemostasis;2019-06-19

3. New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds;Expert Opinion on Investigational Drugs;2017-12-14